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Disclaimer: This guideline is designed primarily as an educational resource for health care providers to help
them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a
successful medical outcome. This guideline should not be considered inclusive of all proper procedures and
tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In
determining the propriety of any speciﬁc procedure or test, the geneticist should apply his or her own
professional judgment to the speciﬁc clinical circumstances presented by the individual patient or specimen. It
may be prudent, however, to document in the patient’s record the rationale for any signiﬁcant deviation from
this guideline.
Abstract: Short stature is a common indication for genetic evaluation.
The differential diagnosis is broad and includes both pathologic causes
of short stature and nonpathologic causes. The purpose of genetic
evaluation for short stature is to provide accurate diagnosis for medical
management and to provide prognosis and recurrence risk counseling
for the patient and family. There is no evidence-based data to guide the
geneticist in an efﬁcient, cost-effective approach to the evaluation of a
patient with short stature. This guideline provides a rubric for the
evaluation of short stature evaluation and summarizes common diag-
noses and clinical testing available. Genet Med 2009:11(6):465–470.
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OBJECTIVE
To provide guidance for medical geneticists and other phy-
sicians regarding genetic evaluation of pathologic short stature.
BACKGROUND INFORMATION
Short stature is a common reason for referral for pediatric
subspecialty evaluation. The purpose of genetic evaluation of
short stature is to provide an accurate diagnosis and to provide
information to the patient and family regarding natural history,
prognosis, available treatment, genetic basis, and recurrence risk.
Potential diagnoses include familial short stature, constitu-
tional delay of growth, occult pulmonary, renal or gastrointes-
tinal disease, endocrinopathies, and genetic disorders. These
categories are not mutually exclusive, and the molecular basis
of many causes of short stature has already been, and continues
to be, elucidated. Depending on the availability of the various
subspecialists in the geographic area and the presence or ab-
sence of associated physical or developmental concerns, the
medical geneticist may be one of the ﬁrst to evaluate an indi-
vidual with a primary indication of short stature or may be
asked to provide consultation regarding genetic testing once a
diagnosis is made by other physicians. If the medical geneticist
is the primary consultant in the evaluation of an individual with
short stature, then he or she must be familiar with the common
nonpathologic conditions associated with short stature in addi-
tion to the teratogenic and genetic causes. One study reported
353 patients referred for genetic evaluation with the primary
indication of short stature (deﬁned as height 3rd centile).
Almost 50% of the patients were considered to have either
constitutional delay of growth or familial short stature. The
most common pathologic diagnosis was chromosome abnor-
mality (19%), primarily Turner syndrome, and its variants. In
3% of cases, a diagnosis of a recognized multiple malformation
syndrome was made, and in almost 2% a previously unrecog-
nized endocrine cause was identiﬁed.1
The majority of information and guidelines for evaluation of
individuals, usually children, with short stature comes from the
pediatric endocrinology literature, particularly addressing eval-
uation for growth hormone deﬁciency and indications for
growth hormone therapy. Although there are a multitude of
publications regarding identiﬁcation of genes associated with
growth and gene defects associated with short stature, there is a
paucity of information directed toward the medical geneticist’s
approach to short stature and appropriate genetic testing. The
most recent publication that speciﬁcally addressed the diagnos-
tic approach to genetic causes of short stature was issued more
than 20 years ago.2 More recently, Kant et al.3 suggested an
algorithm for the molecular diagnosis of short stature, although
syndromes that may present with only minor anomalies were
not included. There is currently no evidence-based literature to
support the diagnostic evaluation of short stature by the medical
geneticist.
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stature, constitutional delay of growth, hypothyroidism, and
occult disease have been ruled out as a cause for short stature.
This guideline is also meant to apply to patients who might
present for genetic evaluation with the chief concern of short
stature, although minor anomalies and some major anomalies
may be identiﬁed. It is not intended to include all genetic
conditions for which short stature may be a feature. Selected
inborn errors of metabolism are included if they are associated
with other physical features or skeletal changes. A brief review
of nonpathologic causes of short stature is included. A diagnos-
tic algorithm is presented along with information regarding
availability and utility of molecular testing for speciﬁc genes
associated with short stature and intrauterine growth restriction
(IUGR).
ANALYSIS OF GROWTH AND PERTINENT
HISTORICAL INFORMATION
The ﬁrst assessment that must be made when a child presents
with short stature is whether a pathologic diagnosis is likely to
be present. There are several factors that one must consider in
the evaluation of short stature, including genetic potential for
growth, rate of growth, and pattern of growth. The deﬁnition
most commonly used for short stature is height-for-age less than
two standard deviations below average for gender, which is
demonstrated on the standard growth curves as a length or
height less than the 3rd centile. Standard growth curves used in
the United States are based on a North American population;
these curves may not apply to all racial and ethnic groups, for
which speciﬁc growth curves may or may not be available.
The single most common useful indicator, in addition to the
absolute height, is growth velocity. Growth velocity is ideally
assessed by reviewing previous growth points or by remeasure-
ment over a 4–6 month interval. Crossing of several centile
lines between 3 years of age and late childhood or early ado-
lescence suggests a pathologic diagnosis. Healthy large infants,
however, often cross centiles in the ﬁrst 3 years of life and
establish a new growth curve more appropriate for their genetic
potential.4 Genetic potential or target height is estimated for
boys by calculating the (father’s height [cm])  (mother’s
height [cm]  13)/2 and for girls (father’s height [cm]) 
(mother’s height [cm]  13)/2. Most children will reach an
adult height within 10 cm of the target height. The centile for
this target height at age 18 years can be helpful to determine if
the child is likely, at his or her present height and age, to reach
that potential.
Analysis of other growth parameters, including weight and
head circumference, are also important in the overall analysis of
a child’s growth pattern. In many pathologic types of short
stature, weight is affected ﬁrst, then height velocity, and ﬁnally
brain growth (documented by head circumference). Low weight
for height is more likely due to nutritional deﬁciency, chronic or
occult disease, or other pathologic conditions. Children with
endocrine disorders often have short stature with normal weight
for height, or even relative obesity.4 Bone age, as a measure of
skeletal maturity, can also be useful, although a delayed bone
age (2 standard deviations compared to the chronologic age)
is nonspeciﬁc and associated with many different causes of
short stature. Finally, analysis of body proportions, such as arm
span-to-height ratio and upper to lower segment ratio are also
helpful in documenting disproportionate short stature.
Another key component of the evaluation is the time of onset
of short stature. The small for gestational age (SGA) infant
presents a special challenge for the medical geneticist. In this
case, detailed information regarding familial birth measure-
ments and growth pattern, maternal stature, parity, presence of
more than one fetus, potential teratogenic exposures, onset of
growth deﬁciency, placental function, amniotic ﬂuid volume,
and the presence or absence of structural anomalies are crucial
to the assessment and evaluation. Restriction in fetal growth in
the later stages of pregnancy is suggestive of placental insufﬁ-
ciency. Maternal health and surgical history are important to
determine potential contribution to fetal growth restriction (e.g.,
maternal vascular disease, history of gastric bypass, or other
surgery that could lead to maternal nutritional deﬁciency).
Pathologic examination of the placenta can yield important
clues to factors contributing to deﬁcient fetal growth.
Fig. 1. Diagnostic algorithm for genetic evaluation of short stature.
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whose length and weight are less than the 10th centile for the
gestational age. By deﬁnition, then, up to 10% of normal infants
could be classiﬁed as SGA. A common alternative deﬁnition is
similar to that for postnatal onset of short stature: two standard
deviations below the average for the gestational age and sex.
Using this latter deﬁnition would likely lead to a higher pro-
portion of infants with true pathologic growth deﬁciency. De-
pending on the cause, duration, and severity of the IUGR, the
infant may or may not exhibit “catch up” growth. This “catch
up” growth in otherwise healthy infants is usually complete by
2 years of age.5
Knowledge of familial growth patterns is also important in
the evaluation of the infant or child with short stature. Consti-
tutional delay of growth is suggested by deceleration of length/
height in the ﬁrst 3 years of life, a normal or near-normal height
velocity during childhood (4–7 cm/year), delayed bone age and
pubertal development, and ﬁnal adult height within the normal
range. Constitutional delay of growth can be familial; careful
questioning of the parents about their childhood growth patterns
and onset of puberty can be helpful. Familial short stature can
be characterized by early deceleration in linear growth depend-
ing on the infant’s birth measurements, a normal or near-normal
growth velocity in childhood, normal bone age and pubertal
development, and height as an adult that is short, but appropri-
ate for the target height.
PATHOLOGIC SHORT STATURE
A diagnostic approach to pathologic short stature is presented
in Figure 1. This approach ﬁrst requires that one differentiates
between isolated short stature and short stature that is associated
with other physical and/or developmental abnormalities. If the
child falls within the latter group, the physician must then
differentiate between proportionate and disproportionate short
stature. A careful physical examination with measurements is
necessary to determine whether there is a disproportionate body
habitus.
The differential diagnosis of isolated short stature includes
nonpathologic and pathologic familial short stature, constitu-
tional growth delay (as discussed earlier), a primary endocri-
nopathy (Table 1), short stature in girls with X chromosome
abnormalities (i.e., Turner syndrome or its variants), or short
stature secondary to mutations in the SHOX gene. Although
most SHOX gene mutations result in characteristic skeletal
changes (Madelung deformity and mesomelia), mutations have
also been identiﬁed in familial and simplex cases of idiopathic
short stature.6 The skeletal changes of dyschondrosteosis may
not be apparent until late childhood or pubertal age and are less
commonly noted in males.6 The reported frequency of SHOX
gene mutations in children with idiopathic short stature has
varied from 1.1% to 12.5% depending on selection criteria and
testing methodology.7 For this reason, skeletal survey should be
considered in some cases of familial short stature to look for
subtle changes that might be diagnostic. If there are any clinical
or radiographic ﬁndings suggestive of dyschondrosteosis,
SHOX gene testing could be considered. Skeletal survey should
also be considered in cases with signiﬁcant short stature (3
standard deviations) if no other diagnosis is apparent.
Review of the clinical, developmental, and family histories
and a detailed physical examination are required to document
the presence of major and/or minor malformations, degree of
developmental delay if present, and other features that would
suggest an underlying chromosome abnormality or recognizable
syndrome.
If physical examination reveals disproportionate short stat-
ure, a skeletal survey (Table 2) is recommended to look for
evidence of a skeletal dysplasia. Molecular genetic testing is
available for conﬁrmation of some of these conditions (Table 3).
In some of the more mild skeletal dysplasias, a skeletal survey
performed in the ﬁrst years of life may not be diagnostic, and
periodic clinical and radiographic reevaluation is necessary. In
other disorders, e.g., chondrodysplasia punctata, the character-
istic features may be missed by taking the radiographs too late.
Table 1. Short stature with endocrinopathy
Short stature
with endocrinopathy Gene Technique Inheritance
Combined pituitary
deﬁciency (CPD)
PROP1 S, TM AR
POU1F1
(PITX1)
S AD, AR
CPD/septooptic
dysplasia
HESX1 S AD, AR, Sp
CPD II (Laron
syndrome)
GHR SA R
CPD III/rigid
cervical spine
LHX3 SA R
Growth hormone
deﬁciency  mental
retardation
SOX3 FISH, Arr XLR
Hypopituitarism,
X-linked
SOX3 Arr XLR
Insulin-like growth
factor 1 deﬁciency
IGF1
a AR
Insulin-like growth
factor 1 resistance
IGF1R
a AD, AR
Isolated growth hormone
deﬁciency type
IA, IB
a
GH1
a AR
Isolated growth hormone
deﬁciency type II
a
GH1
a AD
Thyroid hormone
resistance
THRB S AD, AR
aTesting not available in the United States at the time of manuscript preparation.
AD, autosomal dominant; AR, autosomal recessive; Arr, array comparative
genomic hybridization; FISH, ﬂuorescence in situ hybridization; S, gene sequenc-
ing; TM, targeted mutation analysis.
Table 2. Dysmorphology skeletal survey
AP and lateral views of skull
AP and lateral views of entire spine
AP chest with rib views
AP pelvis
AP long bones
AP hands
AP feet
Lateral ankle and knee
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Selected skeletal dysplasias/dysostoses Gene Technique Inheritance
Achondroplasia FGFR3 TM AD
Albright hereditary osteodystrophy GNAS SA D
Cartilage hair hypoplasia RMRP SA R
Chondrodysplasia punctata
X-linked recessive ARSE A, S, Dup, Del XLR
Rhizomelic, type 1 PEX7 AA R
Rhizomelic, type 2 GNPAT, AGPS A, E AR
X-linked dominant, Conradi-Hunermann EBP A, S XLD
Cleidocranial dysplasia RUNX2 S, Arr AD
Diastrophic dysplasia SLC26A2 SA R
Hereditary multiple exostoses EXT1, EXT2 SA D
Hypochondroplasia FGFR3 TM AD
Hypophosphatasia ALPL A, S AD, AR
Hypophosphatemic rickets
X-linked dominant PHEX S, Dup, Del XLD
Autosomal dominant FGF23 SA D
Kniest dysplasia COL2A1 SA D
Langer mesomelic dwarﬁsm SHOX S, Arr AR
Leri-Weill dyschondrosteosis SHOX S, Arr XLD
Multiple epiphyseal dysplasia COL9A1, COL9A2, COL3, COMP, MATN3 SA D
DTDST AR
Mucopolysaccharidoses
Type 1H, 1S, 1H/S IDUA A, E AR
Type II IDS A, E, S XLR
Types IVA and IVB GALNS, GLB1 A, E AR
Type VI ARSB A, E AR
Type VII SUSB A, E AR
Osteogenesis imperfecta
Type 1 COL1A1, COL1A2 S, B AD
Type 3 COL1A1, COL1A2 S, B AD
Type 4 COL1A1, COL1A2 S, B AD
Type 7 CRTAP SA R
Type 8 LEPRE1 SA R
Pseudoachondroplasia COMP SA D
Pycnodysostosis CTSK
a AR
Schmid metaphyseal dysplasia COL10A1 SA D
Schwartz-Jampel HSPG2
a, LIFR
a AR
Spondyloepiphyseal dysplasia (congenita, tarda) COL2A1 SA D
Spondylepiphyseal dysplasia tarda, X-linked SEDL S XLR
Spondylocarpotarsal synostosis FLNB SA R
Trichorhinophalageal syndrome 1 TRPS1 FISH AD
aTesting not available in the United States at the time of manuscript preparation.
A, analyte (biochemical); AD, autosomal dominant; AR, autosomal recessive; Arr, array comparative genomic hybridization; Del/Dup, deletion/duplication analysis; E, enzyme assay;
FISH, ﬂuorescence in situ hybridization; S, gene sequencing; Sp, sporadic; TM, targeted mutation analysis; XLD, X-linked dominant; XLR, X-linked recessive.
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detailed physical examination may reveal signs that are consis-
tent with a recognizable genetic syndrome. Molecular genetic
testing is available for conﬁrmation of some of these conditions
Table 4. Short stature and other anomalies
Short stature 
other anomalies Gene/locus Technique Inheritance
Aarskog syndrome FGD1 S XLR
Bloom syndrome RECQL3 Cyt, S, TM
a AR
Cockayne syndrome ERCC6, ERCC8 SA R
Cofﬁn-Lowry RPS6KA3
(RSK2)
S, Del/Dup XLD
Cornelia de Lange
syndrome
NIPBL S AD, Sp
SMC1L1 S XLR
SMC3
a AD, Sp
Dubowitz syndrome Unknown AR
Floating Harbor
syndrome
Unknown AD, Sp
Kabuki syndrome Unknown AD, Sp
Langer-Geidion
syndrome
8q24.11-q24.13 Cyt, FISH AD
3M syndrome CUL7
a AR
Mulibrey nanism TRIM37
a AR
Nijmegan breakage
syndrome
NBS1 TM AR
Noonan syndrome PTPN11, RAF1,
KRAS, SOS1
SA D
Prader-Willi
syndrome
15q11-q13 FISH,
Methyl,
UPD
Sp
Robinow syndrome ROR2 SA R
Unknown AD
Rubinstein-Taybi
syndrome
16p13.3,
CREBBP,
EP300
FISH, S AD, Sp
Russell-Silver
syndrome
UPD 7, H19,
others
a
UPD,
Methyl
Sp
Schimke
immunoosseous
dysplasia
SMARCAL1
a AR
SHORT syndrome Unknown AD
SHOX-related short
stature
Xp22.3 Cyt, FISH, S XLD
Smith-Magenis
syndrome
17p11.2/RAI1 Cyt, FISH, S Sp
Turner syndrome Xp Cyt Sp
Velocardiofacial/
DiGeorge
22q11.2,
10p14–13
Cyt, FISH,
Del/Dup
AD, Sp
Williams syndrome 7q11.23 FISH AD, Sp
XLMR-hypotonic
facies
ATRX S, TM,
Del/Dup
XLR
aTesting not available in the United States at the time of manuscript preparation.
Cyt, cytogenetic analysis; AD, autosomal dominant; AR, autosomal recessive;
Del/Dup, deletion/duplication analysis; FISH, ﬂuorescence in situ hybridization;
S, gene sequencing; Sp, sporadic; TM, targeted mutation analysis; XLD, X-linked
dominant; XLR, X-linked recessive.
Table 5. Selected IUGR syndromes
Selected IUGR
syndromes Gene Technique Inheritance
Bloom syndrome RECQL3 Cyt, TM AR
Cockayne syndrome ERCC6,
ERCC8
SA R
Donohue syndrome INSR
a AR
Dubowitz syndrome Unknown AR
Laron syndrome/
CPD
GHR SA R
Insulin-like growth
factor 1 deﬁciency
IGF1
a AR
Insulin-like growth
factor 1 resistance
IGF1R
a AD, AR
Kenny-Caffey
syndrome
TBCE
a AR
Nijmegan breakage
syndrome
NBS1 TM AR
Russell-Silver
syndrome
UPD 7, H19,
others
a
UPD, Methyl Sp
Schimke
immunoosseous
dysplasia
SMARCAL1
a AR
Smith-Lemli-Opitz
syndrome
DHCR7 A, S, TM AR
aTesting for these other causes not available in the United States at the time of
manuscript preparation.
A, analyte (biochemical); AD, autosomal dominant; AR, autosomal recessive;
Cyt, cytogenetic analysis; Methyl, methylation; S, gene sequencing; TM, targeted
mutation analysis; UPD, uniparental disomy.
Table 6. Evaluation of IUGR
Maternal health history
Teratogen history
Pregnancy history
Placental pathology
High resolution chromosome analysis and/or array CGH
Ophthalmologic evaluation
Hearing screen
Evaluation for congenital infection (titers, culture, PCR)
Bone dysplasia survey
Endocrine evaluation with history of persistent hypoglycemia
Cranial imaging of pituitary if endocrine abnormality
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able syndrome, then chromosome analysis should be performed,
which has the added advantage of addressing the potential of
mosaicism. If this analysis is negative, genomic array studies
may be considered to evaluate for changes in genome copy
number.
For the children with intrauterine onset of short stature, the
approach is similar to that of the older child with short stature.
Comparison should be made of the infant’s birth weight, birth
length and birth head circumference, body proportions, and
documentation of major and minor anomalies. Depending on
the age at which the SGA infant is being evaluated, assessment
of the postnatal growth pattern will also yield clues to the
underlying etiology. Selected syndromes associated with IUGR
for which the genetic basis is known are presented in Table 5.
Testing useful in the evaluation of infant with prenatal onset
growth deﬁciency is presented in Table 6.
If no diagnosis is apparent after initial clinical evaluation and
appropriate laboratory or radiographic studies, periodic reas-
sessment is indicated. The timing of reassessment will depend
on the child’s age, whether or not there are other signiﬁcant
developmental or physical features present, the family’s interest
or anxiety, and changes in the family history. A speciﬁc diag-
nosis may become apparent or the differential diagnoses altered
with evolution of the phenotype and additional family history
that may become available. Furthermore, new diagnostic tests
and techniques may allow diagnosis or conﬁrmation of a clin-
ical diagnosis in the future.
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